UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OIVID APPROVAL									
OMB Number:	3235-0	287							
Estimated average burden	hours								
per response		0.5							

Check this box if no longer subject to Section obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Typ	e Responses)																
1. Name and Address of Reporting Person *- WEIL A LORNE						Issuer Name and Ticker or Trading Symbol Ensysce Biosciences, Inc. [LACQ]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
C/O HYDRA MANAGEMENT LLC, 250 WEST 57TH STREET, SUITE 415 (Street)						4. If Amendment, Date Original Filed(Month/Day/Year)							Officer (give title below) Other (specify below)					
					4.								6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person _Form filed by More than One Reporting Person ired, Disposed of, or Beneficially Owned					
NEW YORK, NY 10107 (City) (State) (Zip) 1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Yea																		
(Instr. 3) Date				2A. Deemed Execution Date, if any (Month/Day/Year)		(Instr. 8		or Disposed of (D)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)			Form:	7. Nature of Indirect Beneficial			
						Cod	e V	V An	(A) or (D)	Price				Direct (D) Ownership or Indirect (Instr. 4) (Instr. 4)				
Reminder: F	Report on a so	eparate line for each	class of se			- De	erivative Secu	rities Acq	Pers form valid	n are d OMI Dispose	not required t 3 control nun d of, or Benefic	to responder.	ollection of info nd unless the f				C 1474 (9-02)	
	Conversion		any		Code	5. Number of Derivative Securities Acquired (A) or		Expiration Date		7. Title and Amount of Underlying Securities (Instr. 3 and 4)			Derivative Securities Beneficially Owned	Ownership Form of Derivative Security:	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
					Code	V	(A)	(D)	Date Exercis	sable	Expiration Date	Title	Amount or Number of Shares		Following Reported Transaction(s) (Instr. 4)	Direct (D) or Indirect (I) (Instr. 4)		
Warrants (1)	\$ 11.5	06/30/2021			A(1)		730,110		07/30/	/2021	06/30/2026	Comm	1 /30.110	\$ 1	730,110	D		
Warrants (1)	\$ 11.5	06/30/2021			A(1)		1,000,000		07/30/	/2021	06/30/2026	Comm	11 000 000	\$ 1	1,000,000	I	Hydra LAC LLC (2)	
Warrants (3)	\$ 11.5	06/30/2021			A ⁽³⁾		387,895		07/30/	/2021	06/30/2026	Comm	1 48 / 895	\$ 1	387,895	I	Hydra Managemen LLC (2)	
Warrants (4)	\$ 11.5	06/30/2021			D ⁽⁴⁾			250,000	07/30/	/2021	06/30/2026	Comm	1 250.000	\$ 0	137,895	I	Hydra Managemen LLC (2)	

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
WEIL A LORNE C/O HYDRA MANAGEMENT LLC 250 WEST 57TH STREET, SUITE 415 NEW YORK, NY 10107		X				

Signatures



Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Reflects warrants of Ensysce Biosciences, Inc., formerly known as Leisure Acquisition Corp. (the "Issuer"), which were acquired from the Issuer at a price of \$1.00 per warrant (730,110 warrants by Mr. Weil

at a cost of \$730,110 and 1,000,000 warrants by Hydra LAC LLC (an entity affiliated with Mr. Weil) at a cost of \$1,000,000) in a private placement that closed simultaneously with the closing of the Issuer's

(1) initial public offering which were later exchanged for warrants having the same terms, except that they are non-transferable other than to permitted transferees. Pursuant to the terms of the issuance, such warrants were not eligible to become exercisable unless the Issuer consummated its initial business combination which occurred on June 30, 2021. Mr. Weil served as the Issuer's Executive Chairman until the closing of the business combination.

- Mr. Weil is the managing member of Hydra LAC LLC and the sole member of Hydra Management LLC and disclaims beneficial ownership with respect to the securities except to the extent of his pecuniary (2) interest therein.
- (3) Reflects warrants acquired at a price of \$1.00 per warrant upon the conversion of promissory notes of the Issuer held by Hydra Management LLC reflecting amounts loaned to the Issuer pursuant to the Issuer's expense advancement agreement, which were convertible into warrants at the holder's option. The warrants are on the same terms as the warrants described in note (1) above.
- (4) Reflects warrants surrendered to the Issuer in connection with the Issuer's business combination pursuant to a warrant surrender agreement, for no consideration.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.